Help your uninsured patients get started on VTAMA® (tapinarof) cream, 1% with the Dermavant® RxAssist Program.

Not actual healthcare provider

Healthcare Providers can now digitally submit a patient’s application and supporting documentation for the Dermavant RxAssist Program and get eligible patients started on VTAMA (tapinarof) cream, 1% in as little as 12-72 hours!*

What you’ll be able to access online:

Advantages that matter most to you:

Digital capture of patient and prescriber authorization facilitates timely access to patient support services.


Electronic submission reduces missing, incomplete or illegible information that could cause access delays.


Ability to upload patient medical history, tax documents, income statements and other supporting documentation streamlines the process.

Check your patient’s eligibility:

  • Your patient is Uninsured
  • Your patient is at least 18 years of age and a resident of the United States.
  • Your patient has a prescription for VTAMA (tapinarof) cream, 1%.

Your patient’s annual household income does not exceed 250% of the Federal poverty level:

  • Individuals: $36,450 or less
  • Two-person household: $49,300 or less
  • Three-person household: $62,150 or less
  • Four-person household: $75,000 or less

How to access the Dermavant RxAssist Program

  1. Visit dermavantrx.iassist.com and click 'Healthcare Providers.'
  2. Follow the prompts to fill out and submit the required application.

What’s next after gaining program approval?

  1. You’ll be notified of patient eligibility/next steps via phone, email and/or fax.
  2. Your patient will be contacted to confirm shipping information.
  3. Your patient will begin their therapy journey with VTAMA (tapinarof) cream, 1%!
If patient consent will be needed, the patient is contacted to gather consent digitally via text or phone. If there is missing information, you and/or the patient will be contacted to gather required information.

Ready to get started?

Apply today to help your patients gain access to VTAMA (tapinarof) cream, 1%.

IMPORTANT SAFETY INFORMATION


Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).


You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Subject to financial eligibility requirements. Other terms and restrictions apply.


If you have private insurance coverage, you may be eligible for the MyVTAMA Savings Program.


Income levels are subject to change on an annual basis; the numbers listed are based on the 2023 Federal Poverty Level Guidelines.

Get started on VTAMA® (tapinarof) cream, 1% with the Dermavant® RxAssist Program.

Not actual patients

Our goal at Dermavant is to bring treatment solutions to millions of patients suffering from chronic skin conditions through a best-in-class experience. Dermavant RxAssist is a program developed to help eligible patients gain access to our medication at no cost.*

What you’ll be able to access online:

Check your eligibility:

  • You are Uninsured
  • You are at least 18 years of age and a resident of the United States.
  • You have a prescription for VTAMA (tapinarof) cream, 1%.

Your annual household income does not exceed 250% of the Federal poverty level:

  • Individuals: $36,450 or less
  • Two-person household: $49,300 or less
  • Three-person household: $62,150 or less
  • Four-person household: $75,000 or less

How to access the Dermavant RxAssist Program

  1. Visit dermavantrx.iassist.com and click 'I am a Patient.'
  2. Follow the prompts to fill out and submit the required application.

What’s next after gaining program approval?

  1. Dermavant reviews your eligibility for the program and informs you of program approval status.
  2. If approved, you will receive a call from our pharmacy team to confirm your shipping address.
  3. Your prescription will be shipped directly to you to begin your therapy journey!

Ready to get started?

Apply today to get your medication at no cost and start your therapy journey.

IMPORTANT SAFETY INFORMATION


Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).


You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Subject to financial eligibility requirements. Other terms and restrictions apply.


If you have private insurance coverage, you may be eligible for the MyVTAMA Savings Program.


Income levels are subject to change on an annual basis; the numbers listed are based on the 2023 Federal Poverty Level Guidelines.